Pfizer Inc. logo

PFE

Pfizer Inc.
NYSE
Healthcare
Drug Manufacturers - General
pfizer.com
$.
$0.12(+0.42%)
LIVEupdated just now
O: $28.82H: $29.09L: $28.50

Market Cap

$162.90B

P/E Ratio

37.61

52W High

$29.09

52W Low

$23.58

D

Quality Score

PFE scores 54/100 (D) — momentum is the strongest factor, revenue growth the weakest.

54

/ 100

See the full 7-factor breakdown with PRO.

Upgrade
More historical data is needed for full RSI, MACD, and Bollinger readings.

AI Technical Interpretation

PRO turns PFE's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.

Upgrade to PRO

AI “Why Did It Move?”

Get a ranked, evidence-grounded read on what's likely driving PFE's move today — news, earnings, analyst activity, sector context, and technicals combined.

Upgrade to PRO

Analyst Ratings
28 analysts

ConsensusBuy
Strong Buy2
Buy8
Hold16
Sell1
Strong Sell1
Avg price target+0.09%
$28.61from $28.58
Low $25.00Median $28.00High $35.75

Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.

AI Fair Value Estimate

Get an AI analyst's take on whether PFE looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.

Upgrade to PRO

AI Earnings Preview

Next report 2026-11-03 · in 63 days

Consensus estimates

EPS

$0.76

Revenue

$15.95B

Recent EPS surprises

2026-06Beat +13%2026-03Beat +4%2025-12Beat +16%2025-09Beat +37%

Unlock the AI preview for PFE

Get an AI analyst's read on the setup, what to watch, and risks heading into the print.

Upgrade to PRO
Post-Earnings Recap· reported 2026-06-30

Unlock the post-earnings recap for PFE

Get an AI analyst's read on how the report went and how the stock reacted.

Upgrade to PRO

Dividend
Quarterly

Forward yield

6.02%

Annual / share

$1.72

Last ex-date

Jul 24, 2026

Last payment

Sep 1, 2026

Recent payments

Ex-date Jul 24, 2026$0.43
Ex-date May 8, 2026$0.43
Ex-date Jan 23, 2026$0.43
Ex-date Nov 7, 2025$0.43
Ex-date Jul 25, 2025$0.43
Ex-date May 9, 2025$0.43
Ex-date Jan 24, 2025$0.43
Ex-date Nov 8, 2024$0.42

Forward annual dividend from the declared rate (or latest payment × frequency) · via Yahoo Finance & Financial Modeling Prep.

AI Dividend Safety

Get an AI read on whether PFE's dividend looks sustainable — earnings coverage, payout history, and the risks worth researching.

Upgrade to PRO

Insider Trading

No recent insider trading activity is available for PFE.

Financial Statements

MetricFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$62.58B$63.63B$59.55B$100.33B$81.29B
Gross Profit$44.01B$41.85B$30.34B$62.09B$46.88B
Operating Income$15.44B$16.48B$5.29B$37.55B$20.79B
EBITDA$15.10B$18.13B$9.56B$41.03B$30.79B
Net Income$7.77B$8.02B$2.13B$31.36B$22.15B
EPS (Diluted)$1.36$1.41$0.37$5.47$3.88

Financial statements via Financial Modeling Prep. Figures as reported; not investment advice.

AI Stock Analysis

Unlock an in-depth, balanced bull/bear breakdown of PFE — catalysts, risks, and a plain-language read on the fundamentals.

Upgrade to PRO

Investor Copilot Notebook

Keep a thesis on PFE

Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.

Upgrade to PRO

Investment Thesis Timeline

See PFE's full timeline

Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.

Upgrade to PRO
TradingView
Sponsored

Deeper technical charting, indicators, and pattern tools that complement XMarketPro's research.

Open advanced charts

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

TrendSpider
Sponsored

Automated technical analysis, charting, and pattern recognition for active traders.

Explore automated technical analysis

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Seeking Alpha
Sponsored

Another independent research perspective to compare against XMarketPro's own analysis.

Compare with additional research

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Interactive Brokers
Sponsored

A well-established U.S. brokerage for investors moving from research into execution.

Explore brokerage options

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

PFE logo
About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Visit pfizer.com

Key Statistics

Open
$28.82
Prev Close
$28.46
Day High
$29.09
Day Low
$28.50
Volume
25.45M
Market Cap
$162.90B
P/E Ratio
37.61
EPS
$0.76
Beta
0.28
Dividend Yield
+6.04%
52W High
$29.09
52W Low
$23.58
Analyst Target